Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15007MR)

This product GTTS-WQ15007MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15007MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7142MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ1577MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ2063MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ15793MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ14936MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8339MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ5127MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ13717MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW